- Q1 2024 Relmada Therapeutics Inc Earnings Call TranscriptMay 08, 2024$3.83 (+0.26%)Earnings
- Q4 2023 Relmada Therapeutics Inc Earnings Call TranscriptMar 19, 2024$5.37 (-2.72%)Earnings
- Q3 2023 Relmada Therapeutics Inc Earnings Call TranscriptNov 08, 2023$3 (-1.64%)Earnings
- Q2 2023 Relmada Therapeutics Inc Earnings Call TranscriptAug 08, 2023$2.54 (-3.79%)Earnings
- Relmada Therapeutics Inc at Goldman Sachs Healthcare Conference TranscriptJun 14, 2023
- Relmada Therapeutics Inc at Jefferies Healthcare Conference TranscriptJun 08, 2023
- Q1 2023 Relmada Therapeutics Inc Earnings Call TranscriptMay 11, 2023$3.17 (-3.06%)Earnings
- Q4 2022 Relmada Therapeutics Inc Earnings Call TranscriptMar 23, 2023$2.32 (-0.85%)Earnings
- Relmada Therapeutics Inc Top-line Results from Phase 3 RELIANCE I Trial for REL-1017 as an Adjunctive Treatment for Major Depressive Disorder - Corporate Call TranscriptDec 07, 2022
- Q3 2022 Relmada Therapeutics Inc Earnings Call TranscriptNov 10, 2022$5.84 (+1.39%)Earnings
- Q2 2022 Relmada Therapeutics Inc Earnings Call TranscriptAug 11, 2022$27.82 (-4.99%)Earnings
- Relmada Therapeutics Inc at Goldman Sachs Global Healthcare Conference TranscriptJun 14, 2022
- Q1 2022 Relmada Therapeutics Inc Earnings Call TranscriptMay 05, 2022$22.4 (-7.70%)Earnings
- Q4 2021 Relmada Therapeutics Inc Earnings Call TranscriptMar 23, 2022$23.33Earnings
- Relmada Therapeutics Inc Results of Human Abuse Potential Study of REL-1017 vs. Ketamine - Corporate Call TranscriptFeb 23, 2022
- Q3 2021 Relmada Therapeutics Inc Earnings Call TranscriptNov 11, 2021$25.66 (+3.22%)Earnings
- Relmada Therapeutics Inc at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 10, 2021
- Q2 2021 Relmada Therapeutics Inc Earnings Call TranscriptAug 10, 2021$23 (+1.28%)Earnings
- Relmada Therapeutics Inc REL-1017 Clinical Data Update Call TranscriptJul 27, 2021
- Q1 2021 Relmada Therapeutics Inc Earnings Call TranscriptMay 12, 2021$33.61 (-3.81%)Earnings
- Q4 2020 Relmada Therapeutics Inc Earnings Call TranscriptMar 23, 2021$34.34 (-3.40%)Earnings
Relmada Therapeutics Inc at Jefferies Healthcare Conference Transcript
Okay. We're going to get started with our next session. Hi, everyone. I'm Andrew Tsai, senior biotech analyst here at Jefferies. Thanks for tuning in, and it's my pleasure to have the Relmada team joining me today. I have to the left of me, Sergio Traversa, CEO; and to the left of him, Cedric O'Gorman, CMO. Welcome both of you.
' -
Thank you.
So maybe Sergio, Cedric, for those in the audience who are less familiar with the Relmada story, could you possibly give us an overview about your company, what you're trying to achieve, what stage of development you're in and the next set of catalysts we can expect over the coming months?
Okay. Well, first, Andrew, thank you very much for inviting us at the Jefferies conference. And welcome, everyone interested. And thanks for the
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)